ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > CCR5

CCR5

概要

Name:C-C chemokine receptor type 5
Target Synonym:CCR-5,Chemokine (C-C Motif) Receptor 5 (Gene/Pseudogene),C-C Motif Chemokine Receptor 5 A159A,Chemokine Recptor CCR5 Delta32,C-C Chemokine Receptor Type 5,Chemokine Receptor CCR5,CD195 Antigen,C-C CKR-5,CCCKR5,IDDM22,CKR-5,CKR5,Receptors, CCR5,C-C Motif Chemokine Receptor 5,CD195,CHEMR13,CCR5,HIV-1 fusion coreceptor,C-C Motif Chemokine Receptor 5 (Gene/Pseudogene),Chemokine (C-C Motif) Receptor 5,CC-CKR-5,CMKBR5
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:13
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

ACRO Quality

生物活性データの一部

CHEK-ATP043-Cell-based assay
 CCR5 FACS

FACS assay shows that Anti-CCR5 antibody can bind to HEK293/Human CCR5 Stable Cell Line. HEK293/Human CCR5 Stable Cell Line was red line, Negative control HEK293 cells was grey line (QC tested).

CC5-H52D1-SPR
 CCR5 SPR

Human CCR5, Flag,His Tag (Cat. No. CC5-H52D1) captured on CM5 chip via anti-His antibody can bind Anti-CCR5 antibody (Human IgG1) with an affinity constant of 0.0737 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).

CC5-H52D1-SPR
 CCR5 SPR

Purified NA/LE Mouse Anti-Human CD195 (Clone: 2D7) (Mouse IgG2a) captured on CM5 chip via anti-mouse antibodies surface can bind Human CCR5, Flag,His Tag (Cat. No. CC5-H52D1) with an affinity constant of 7.51 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).

Synonym Name

CCR5,CMKBR5,CD195,CC-CKR-5,CHEMR13

Background

Receptor for a number of inflammatory CC-chemokines including CCL3/MIP-1-alpha, CCL4/MIP-1-beta and RANTES and subsequently transduces a signal by increasing the intracellular calcium ion level. May play a role in the control of granulocytic lineage proliferation or differentiation.5 Publications (Microbial infection) Acts as a coreceptor (CD4 being the primary receptor) of human immunodeficiency virus-1/HIV-1.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Maraviroc MVC; UK-427857 Approved Viiv Healthcare Celsentri, Selzentry United States HIV Infections Viiv Healthcare Co 2007-08-06 HIV Infections; Acquired Immunodeficiency Syndrome; Hematologic Neoplasms; Hematopoietic stem cell transplantation (HSCT); Hypertriglyceridemia; Arthritis, Rheumatoid; Graft vs Host Disease; Coronavirus Disease 2019 (COVID-19); Kidney Diseases; Stroke; AIDS Dementia Complex; Cardiovascular Diseases; Inflammation; HIV Seropositivity; Sarcoma, Kaposi Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Leronlimab PRO-140; PA-14; HuPRO-140 Phase 3 Clinical Cytodyn Inc HIV Infections; Solid tumours; Metabolic Dysfunction-Associated Steatotic Liver Disease; Triple Negative Breast Neoplasms; Graft vs Host Disease; Coronavirus Disease 2019 (COVID-19); Colorectal Neoplasms; HIV Seropositivity Details
Cenicriviroc mesylate CCR5/CCR2 antagonist; TBR-652; CVC; TAK-652 Phase 3 Clinical Tobira Therapeutics Inc, Takeda Pharmaceutical Co Ltd Prediabetic State; HIV Infections; Acquired Immunodeficiency Syndrome; Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Liver Cirrhosis; Coronavirus Disease 2019 (COVID-19); AIDS Dementia Complex; Cholangitis, Sclerosing; Hepatic Insufficiency; Obesity; Cognition Disorders Details
SB-728-T SB-728mR-T; SB-728-T Phase 2 Clinical Sangamo Biosciences HIV Infections Details
Vicriviroc SCH-D; MK-4176; SCH-417; Sch-417690 Phase 2 Clinical Merck & Co Inc HIV Infections; Acquired Immunodeficiency Syndrome; Colorectal Neoplasms Details
BMS-813160 BMS-813160 Phase 2 Clinical Bristol-Myers Squibb Company Pancreatic Neoplasms; Colorectal Neoplasms; Hyperplasia; Diabetic Nephropathies; Carcinoma, Pancreatic Ductal; Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Cenicriviroc mesylate/Tropifexor LJC-242 Phase 2 Clinical Novartis Pharma Ag Metabolic Dysfunction-Associated Steatotic Liver Disease Details
AGT 103-T AGT 103-T Phase 1 Clinical American Gene Technologies International Inc HIV Infections Details
Thioraviroc Phase 1 Clinical Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences HIV Infections Details
BMS-687681 BMS-687681 Phase 1 Clinical Bristol-Myers Squibb Company Neoplasms Details
SB-728-HSC SB-728-HSC; SB-728-HSPC; SB-728mR-HSPC Phase 1 Clinical Sangamo Biosciences HIV Infections; HIV Seropositivity Details
LF-0376 LF-0376 Phase 1 Clinical Wuxi Hillhouse biomedicine Technology Co Ltd Solid tumours; Liver Neoplasms; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Colorectal Neoplasms; Lymphoma Details
OB-002 OB-002; OB-002M; OB-002O; OB-002H; OB-002C; 5P12-RANTES; 5P12-RANTES-E66S Phase 1 Clinical Mintaka Medical Research Foundation HIV Infections; Stomach Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Neoplasm Metastasis Details

This web search service is supported by Google Inc.

totopphone